ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,638.50
-2.00 (-0.12%)
Last Updated: 14:02:29
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.12% 1,638.50 1,638.00 1,638.50 1,647.00 1,634.00 1,638.50 810,281 14:02:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.66 67.33B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,640.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.52 billion. Gsk has a price to earnings ratio (PE ratio) of 13.70.

Gsk Share Discussion Threads

Showing 19201 to 19224 of 33100 messages
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
DateSubjectAuthorDiscuss
13/2/2019
07:47
I (for one) am optimistic …. that's why I keep buying GSK !!
tradermichael
13/2/2019
05:58
Glaxo: reinvigorated pipeline can support bumper divi
The pipeline at GlaxoSmithKline (GSK) has been ‘reinvigorated’ and Jefferies says the model that allows it to pay the highest dividend in the EU large-cap pharmaceutical space is sustainable.
Analyst Peter Welford reiterated his ‘buy’ recommendation and target price of £17.50 on the stock after raising his earnings per share estimate by 7%. The shares were trading at £15.53 yesterday.
‘GSK offers the highest dividend yield of EU large-cap pharma, which our model suggests is sustainable… at least until the proposed split of the consumer healthcare joint venture,’ he said.
‘We see the strategic rationale for a UK demerger within three years as an opportunity to crystallise value, plus consumer standalone can support higher debt levels.’
Welford said the recent £4 billion acquisition of Tesaro did boost the group’s oncology pipeline and the cancer specialism would ‘prove critical’ but even so he was ‘not enamoured by the deal’.



If nothing else it's a change from the ceaseless pessimism here.

grahamite2
12/2/2019
18:02
Quite right Dr. A lot of the goodness has now gone.
zicopele
12/2/2019
18:02
Good fine, must admit did not think Mylan ready to go and at such a big discount.
montyhedge
12/2/2019
17:48
Monty - hence the previous comments about generics and the immediate impact on profits. Your replies were puzzling to be polite. ;)
alphorn
12/2/2019
17:43
Wow they must of been all ready to go, 70% discount. GSK surely will have to match. Rather have the original.But the GSK Global President of vaccines selling shares, did not wait for ex div. not that encouraging in y opinion.
montyhedge
12/2/2019
17:02
Actually Milan wasted 18 months getting the data right to prove equivalence.
dr biotech
12/2/2019
16:41
Mylan did not waste any time.
zicopele
12/2/2019
16:36
WB: That's only possible when there is no original research cost
tradermichael
12/2/2019
16:35
Where is Monty when he is needed, telling us that he would buy Advair rather than the 70% cheaper generic?

Probably on IAG telling everyone that hedging oil and lower oil price can both be beneficial simultaneously for airline stock

zicopele
12/2/2019
16:20
”Mylan launches generic version of Glaxo's Advair Diskus at 70% discount”


Mylan N.V. (MYL +1.6%) announces the U.S. commercial launch of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), its generic version of GlaxoSmithKline's (GSK +0.4%) asthma and COPD med Advair Diskus.
The company says its wholesale cost is 70% less that Glaxo's branded product and 67% less than its authorized generic.

wbecki
12/2/2019
15:39
All the oil majors results were remarkable. They are cash generating machines.

Even minnows like premier oil which are highly indebted are reducing debt.

They have all seriously reduced cash cost per barrel equivalent.


As for GSK. I am a buyer sub 1500.

zicopele
12/2/2019
15:35
In a way BP great results with oil down 21% last six months. That must have boosted IAG, I know they hedge so that also helps.
montyhedge
12/2/2019
15:01
I guess you have traded experian then.

BP and IAG must be negatively correlated.

zicopele
12/2/2019
14:57
Yes BP good. But for traders like me, big bonus no stamp duty.
montyhedge
12/2/2019
14:53
So, I now have another 2420 shares in line for a 23p dividend (If I hold!)
tradermichael
12/2/2019
14:50
zico - yes, the day's low was 1541.60p and I was able to programme a buy with a limit of 1543.00p and it was 'bettered' at 1542.856 while I was away from the computer ….. ;0)
tradermichael
12/2/2019
14:49
You reckon Monty? I am long BP.
zicopele
12/2/2019
14:19
When the GSK President of global vaccines sells, even before ex dividend date, not that encouraging.
montyhedge
12/2/2019
14:07
Would have been just about the days low so well done on that. TM is one of the more credible posters on here that doesn't have a retrospective broker that others seem to use.
dr biotech
12/2/2019
14:05
I sold my GSK at 1560p see what happens, switched into IAG (British Airways) looks cheap to me and no stamp duty to pay, at least the Chancellor does not get it.
montyhedge
12/2/2019
13:55
I did not think they went that low yesterday. 1542?
zicopele
12/2/2019
08:20
I bought yesterday at 15.57pm, price 1542.856 …… ;0)
tradermichael
11/2/2019
22:20
Too high above £15
zicopele
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older

Your Recent History

Delayed Upgrade Clock